Lactoferrin variants and uses thereof

• US 6,111,081 A
• Filed: 05/30/1997
• Issued: 08/29/2000
• Est. Priority Date: 05/31/1996
• Status: Expired due to Term

• Current Assignee: Baylor College of Medicine (Baylor College)
• Original Assignee: Baylor College of Medicine (Baylor College)
• Inventors: Ward, Pauline P., Conneely, Orla M.
• Primary Examiner(s): Achutamurthy, Ponnathapura
• Assistant Examiner(s): Moore, William W.
• Application Number:
  US08/866,544
• Time in Patent Office: 1,187 Days
• Field of Search: 530/350, 530/395, 530/400, 435/69.1, 435/252.3, 435/254.4, 435/254.3, 435/320.1, 435/476, 435/477, 435/484, 536/23.5
• US Class Current: 530/400
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 31/04 Antibacterial agents
• CPC Class Codes: C07K 14/79 Transferrins, e.g. lactoferrins, ovotransferrins

Abstract

The present invention is directed to recombinant nucleic acids encoding lactoferrin variants and portions thereof, having modified iron-binding capacity, and to vectors comprising same recombinant nucleic acids. The present invention is further directed to methods of producing such vectors, and to transfected cells harboring the same. Methods for the production of lactoferrin variants and portions thereof, in various eukaryotic or prokaryotic cells are also provided. Finally, the invention is directed to lactoferrin variants and portions thereof encoded by the nucleic acids of the invention and produced by the processes of the invention. Thus, the invention provides an efficient and economical means for the production of recombinant lactoferrin variants and portions thereof.

Claims

1. A nucleic acid sequence encoding a lactoferrin variant or portion thereof, wherein said portion is further defined to comprise an amino acid sequence corresponding to at least one iron binding site of lactoferrin, and wherein the lactoferrin variant or portion thereof has a modified iron binding capacity, and wherein the amino acid sequence corresponding to at least one iron binding site of lactoferrin comprises a mutation or deletion of one or more amino acids selected from the group consisting of Asp 396, Tyr 93. Tyr 193 and His 254 in the amino-terminal lobe and Asp 396. Tyr 436. Tyr 529 and His 598 in the carboxy-terminal lobe.

3. A recombinant vector comprising:

(a) a promoter;

(b) DNA encoding the lactoferrin variant or portion thereof of claim 1; and

(c) transcription and translation initiation and termination sequences;

wherein said vector is capable of producing the lactoferrin variant and expressing same as a processed protein.

4. A vector adapted for the expression of a lactoferrin variant or portion thereof in a eukaryotic cell, wherein said vector comprises DNA encoding a lactoferrin variant protein or portion thereof of claim 1 and regulatory elements necessary for the expression of said DNA in said cell.

5. A vector comprising:

(a) a nucleic acid encoding the lactoferrin variant or portion thereof of claim 1; and

(b) a promoter, and transcription and translation initiation and termination sequences;

wherein said vector is used for the expression of human lactoferrin in a eukaryotic cell.

7. A transformed eukaryotic cell comprising the vector of claim 5.

8. The eukaryotic cell of claim 7, wherein said cell is selected from the group consisting of fungal, mammalian and insect cells.

9. The eukaryotic cell of claim 8, wherein said eukaryotic cell is a fungal cell selected from the group consisting of Aspergillus oryzae, Aspergillus niger, Aspergillus nidulans and Aspergillus awamori.

13. A method for producing the lactoferrin variant or portion thereof of claim 1 which comprises the following steps:

(a) transforming a eukaryotic cell with a vector containing;

i) the nucleic acid of claim 1; and

ii) a promoter, and transcription and translation initiation and termination sequences;

wherein said vector is adapted for the expression of the lactoferrin variant or portion thereof in a eukaryotic cell; and

(b) culturing said transformed eukaryotic cell in a suitable nutrient medium until lactoferrin variant protein is formed, secreted into the nutrient medium, and isolated therefrom.

14. A lactoferrin variant or portion thereof encoded by the nucleic acid of claim 1.

2. A nucleic acid sequence encoding a lactoferrin variant selected from the group consisting of MN-2Y, MC-2Y and MNC-4Y.

6. A vector selected from the group consisting of p26MN-2Y, p26MC-2Y and p26MNC-4Y.

10. A transformed eukaryotic cell comprising a vector of claim 6.

11. The eukaryotic cell of claim 10, wherein said cell is selected from the group consisting of fungal, mammalian and insect cells.

12. The eukaryotic cell of claim 11, wherein said eukaryotic cell is a fungal cell selected from the group consisting of Aspergillus oryzae, Aspergillus niger, Aspergillus nidulans and Aspergillus awamori.

15. A lactoferrin variant selected from the group consisting of MN-2Y, MC-2Y and MNC-4Y.